Merck acquiring Cidara Therapeutics in $9.2bn deal
American multinational pharmaceutical company Merck has signed a definitive agreement to acquire biotech group Cidara Therapeutics, valuing the deal at about $9.2 billion The deal is expected to close in 1Q 2026 once customary antitrust and tender-offer conditions are met. Both boards have approved the transaction. At the centre of the deal is CD388, Cidara’s first-in-class, long-acting antiviral engineered to…
Genmab broadens late-stage portfolio with $8bn Merus acquisition
Copenhagen-based antibody therapeutics company Genmab has agreed to acquire Merus in a deal valuing the Dutch–U.S. oncology company at approximately $8bn. The move brings late-stage bispecific antibody petosemtamab into Genmab’s pipeline. Petosemtamab is in two Phase 3 trials for head and neck cancer, carries two FDA Breakthrough Therapy Designations, and could launch as early as 2027. According to Alcon’s management,…